New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
06:57 EDTACRX, AUXL, BCRX, IRWD, KERX, SLXP, CBST, QCORBiotech weakness a buying opportunity, says Mizuho
Mizuho said the recent weakness in biotech will prove transient and has created buying opportunities in AcelRx (ACRX), Auxilium (AUXL), BioCryst (BCRX), Ironwood (IRWD), Keryx (KERX), Salix (SLXP), Cubist (CBST), and Questcor (QCOR).
News For ACRX;AUXL;BCRX;IRWD;KERX;SLXP;CBST;QCOR From The Last 14 Days
Check below for free stories on ACRX;AUXL;BCRX;IRWD;KERX;SLXP;CBST;QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 14, 2014
15:09 EDTQCORQuestcor rises after S-4 effective, interest from other suitors disclosed
Subscribe for More Information
07:07 EDTSLXPFDA says RELISTOR can be approved on data submitted in sNDA
Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the Food and Drug Administration has informed Salix that RELISTOR can be approved on the data submitted in the sNDA. The FDA Office of Drug Evaluation III responded to the company’s formal appeal filed in response to the Complete Response Letter of July 27, 2012 to the supplemental NDA ) for RELISTOR. The Agency’s letter stated that, “Salix’s request that FDA approve the supplemental NDA for RELISTOR subcutaneous injection for the treatment of opioid-induced constipation in patients with chronic non-cancer pain based on the submitted data is granted.” This request for a proposal for a post-marketing observational study is in accordance with recommendations of the June 11-12, 2014 meeting of the Anesthetic and Analgesic Drug Product Advisory Committee. Salix will work with the DGIEP in an effort to provide information to the division that will enable the division to approve RELISTOR for use by patients with chronic non-cancer pain and experiencing OIC.
07:04 EDTQCORMallinckrodt and Questcor update transaction
Mallinckrodt (MNK) and Questcor (QCOR) announced that the registration statement on Form S-4 filed with the SEC by Mallinckrodt on May 16 and amended on July 11 which includes a joint proxy statement of Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, was declared effective on July 11. The companies have also each scheduled shareholder meetings on August 14 for shareholders of record on July 9 to consider (i) in the case of Mallinckrodt, its proposal to issue its ordinary shares in connection with its proposed acquisition of Questcor and (ii) in the case of Questcor, approval of the merger agreement with Mallinckrodt and related matters. The transaction is currently expected to be completed in August.
05:51 EDTCBSTAchaogen appoints Dr. Ian Friedland as Chief Medical Officer
Subscribe for More Information
July 11, 2014
16:46 EDTSLXPStocks end week lower on European, Fed concerns
Subscribe for More Information
09:19 EDTSLXPSalix price target raised to $165 from $130 at Sterne Agee
Sterne Agee increased its price target on Salix (SLXP) to reflect recent data on the company's Xifaxan irritable bowel treatment. The firm views the data as very strong and now sees a 90% chance that the treatment will be approved. Sterne Agee also cited the reduction of the company's taxes following its merger with Cosmo Tech as a reason for its target increase. Sterne keeps a Buy rating on Salix.
09:09 EDTQCOROn The Fly: Pre-market Movers
Subscribe for More Information
06:39 EDTQCORQuestcor reports Acthar adverse effects data, NY Times says
The number of patients who reported an adverse effect last year while taking Questcor's (QCOR) Acthar drug amounted to almost 5% of prescriptions dispensed, the company stated in a regulatory filing released yesterday, according to The New York Times. The filing marked the first time that the company has disclosed any difficulties experienced by Acthar patients, the newspaper added. Questcor has agreed to be bought by Mallinckrodt (MNK). Reference Link
July 10, 2014
08:05 EDTSLXPSalix price target raised to $150 from $125 at Brean Capital
Subscribe for More Information
06:56 EDTSLXPSalix price target raised to $192 from $126 at Piper Jaffray
Subscribe for More Information
06:55 EDTSLXPSalix growth outlook, value compelling, says Stifel
Following Salix's Analyst Day, Stifel believes that Salix's shares offer one of the most compelling growth and value opportunities among specialty drug companies it covers. The firm thinks that data for the company's Xifaxan data was strong and is likely to satisfy the FDA. The firm is upbeat on the company's Cosmo deal and thinks the deal is underappreciated. It keeps a Buy rating on Salix.
July 9, 2014
10:29 EDTSLXPSalix prospects as takeover target debated after inversion deal
Subscribe for More Information
10:19 EDTSLXPSalix targets 3-5 year goal of adjusted net income 32%-37% of revenue
Subscribe for More Information
10:15 EDTSLXPSalix repeats FY14 adjusted EPS view about $6.33, consensus $6.52
Subscribe for More Information
09:13 EDTSLXPOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTSLXPSalix deal suggests not likely to look to sell in near-term, says JMP Securities
After Salix announced a merger with Irish-domiciled Cosmo Technologies, JMP Securities thinks the deal may disappoint investors since it's not immediately materially accretive. The firm contends that the deal suggests that Salix is unlikely to look to sell itself in the near-term ,although it thinks that the company still remains a takeover target. JMP Securities keeps an Outperform rating on the stock.
07:53 EDTSLXPSalix near-term takeout unlikely after inversion deal, says Leerink
Subscribe for More Information
07:46 EDTSLXPSalix tax inversion deal disappointing, says UBS
Subscribe for More Information
06:41 EDTSLXPSalix rationale behind Cosmo deal compelling, says Piper Jaffray
Subscribe for More Information
06:20 EDTSLXPSalix to host conference call
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use